On Friday, Day One Biopharmaceuticals Inc (NASDAQ: DAWN) was -7.05% drop from the session before settling in for the closing price of $14.32. A 52-week range for DAWN has been $11.30 – $18.07.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 68.09%. With a float of $69.23 million, this company’s outstanding shares have now reached $87.23 million.
In an organization with 155 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 90.66%, operating margin of -733.66%, and the pretax margin is -290.14%.
Day One Biopharmaceuticals Inc (DAWN) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Day One Biopharmaceuticals Inc stocks. The insider ownership of Day One Biopharmaceuticals Inc is 32.40%, while institutional ownership is 81.55%. The most recent insider transaction that took place on Nov 08 ’24, was worth 295,229. In this transaction HEAD OF R&D of this company sold 18,255 shares at a rate of $16.17, taking the stock ownership to the 1,067,535 shares. Before that another transaction happened on Nov 11 ’24, when Company’s HEAD OF R&D sold 10,000 for $16.10, making the entire transaction worth $160,994. This insider now owns 1,057,535 shares in total.
Day One Biopharmaceuticals Inc (DAWN) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.64 earnings per share (EPS) during the time that was less than consensus figure (set at -0.57) by -0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 68.09% per share during the next fiscal year.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Trading Performance Indicators
You can see what Day One Biopharmaceuticals Inc (DAWN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 14.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.01, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -1.00 in one year’s time.
Technical Analysis of Day One Biopharmaceuticals Inc (DAWN)
Let’s dig in a bit further. During the last 5-days, its volume was 1.13 million. That was better than the volume of 0.96 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 8.27%. Additionally, its Average True Range was 0.80.
During the past 100 days, Day One Biopharmaceuticals Inc’s (DAWN) raw stochastic average was set at 18.44%, which indicates a significant increase from 0.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.23% in the past 14 days, which was higher than the 43.25% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.42, while its 200-day Moving Average is $14.65. However, in the short run, Day One Biopharmaceuticals Inc’s stock first resistance to watch stands at $14.01. Second resistance stands at $14.70. The third major resistance level sits at $15.06. If the price goes on to break the first support level at $12.96, it is likely to go to the next support level at $12.60. The third support level lies at $11.91 if the price breaches the second support level.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Key Stats
There are 100,846K outstanding shares of the company, which has a market capitalization of 1.25 billion. As of now, sales total 0 K while income totals -188,920 K. Its latest quarter income was 93,760 K while its last quarter net income were 37,040 K.
